Identifying priorities for research on financial risk protection to achieve universal health coverage: a scoping overview of reviews.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
09 03 2022
Historique:
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 28 4 2022
Statut: epublish

Résumé

Financial risk protection (FRP) is an indicator of the Sustainable Development Goal 3 universal health coverage (UHC) target. We sought to characterise what is known about FRP in the UHC context and to identify evidence gaps to prioritise in future research. Scoping overview of reviews using the Arksey & O'Malley and Levac & Colquhoun framework and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews reporting guidelines. MEDLINE, PsycINFO, CINAHL-Plus and PAIS Index were systematically searched for studies published between 1 January 1995 and 20 July 2021. Records were screened by two independent reviewers in duplicate using the following criteria: (1) literature review; (2) focus on UHC achievement through FRP; (3) English or French language; (4) published after 1995 and (5) peer-reviewed. Two reviewers extracted data using a standard form and descriptive content analysis was performed to synthesise findings. 50 studies were included. Most studies were systematic reviews focusing on low-income and middle-income countries. Study periods spanned 1990 and 2020. While FRP was recognised as a dimension of UHC, it was rarely defined as a concept. Out-of-pocket, catastrophic and impoverishing health expenditures were most commonly used to measure FRP. Pooling arrangements, expansion of insurance coverage and financial incentives were the main interventions for achieving FRP. Evidence gaps pertained to the effectiveness, cost-effectiveness and equity implications of efforts aimed at increasing FRP. Methodological gaps related to trade-offs between single-country and multicountry analyses; lack of process evaluations; inadequate mixed-methods evidence, disaggregated by relevant characteristics; lack of comparable and standardised measurement and short follow-up periods. This scoping overview of reviews characterised what is known about FRP as a UHC dimension and found evidence gaps related to the effectiveness, cost-effectiveness and equity implications of FRP interventions. Theory-informed mixed-methods research using high-quality, longitudinal and disaggregated data is needed to address these objectives.

Identifiants

pubmed: 35264342
pii: bmjopen-2021-052041
doi: 10.1136/bmjopen-2021-052041
pmc: PMC8915291
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e052041

Subventions

Organisme : CIHR
ID : 407149
Pays : Canada

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Int J Equity Health. 2021 Mar 3;20(1):70
pubmed: 33658033
Front Public Health. 2019 Apr 26;7:102
pubmed: 31080792
Int J Equity Health. 2019 Aug 28;18(1):134
pubmed: 31462303
Res Nurs Health. 2010 Feb;33(1):77-84
pubmed: 20014004
Milbank Q. 2011 Jun;89(2):206-25
pubmed: 21676021
Risk Manag Healthc Policy. 2020 Oct 02;13:1879-1904
pubmed: 33061721
Lancet. 2020 Oct 17;396(10258):1250-1284
pubmed: 32861314
Lancet. 2014 Jan 18;383(9913):277-9
pubmed: 23953765
JBI Evid Synth. 2020 Oct;18(10):2119-2126
pubmed: 33038124
Cost Eff Resour Alloc. 2020 May 15;18:17
pubmed: 32467673
Lancet Glob Health. 2018 Feb;6(2):e152-e168
pubmed: 29248365
Clinicoecon Outcomes Res. 2021 May 11;13:359-375
pubmed: 34007193
Health Policy. 2015 Sep;119(9):1153-63
pubmed: 26183890
Reprod Health Matters. 2012 Jun;20(39):50-61
pubmed: 22789082
Int J Environ Res Public Health. 2020 Mar 19;17(6):
pubmed: 32204527
PLoS One. 2019 Jun 14;14(6):e0217278
pubmed: 31199815
BMC Pregnancy Childbirth. 2017 Aug 31;17(1):262
pubmed: 28854877
Int J Surg. 2021 Jun;90:105956
pubmed: 33940199
Eur Urol Oncol. 2021 Jun;4(3):396-404
pubmed: 33820747
BMC Int Health Hum Rights. 2015 Jul 04;15:17
pubmed: 26141806
J Clin Epidemiol. 2007 Jun;60(6):598-9
pubmed: 17493518
Int J Equity Health. 2021 Feb 26;20(1):66
pubmed: 33637090
Cochrane Database Syst Rev. 2017 Sep 11;9:CD011084
pubmed: 28891235
Int J Equity Health. 2013 Jan 22;12:9
pubmed: 23339606
JMIR Public Health Surveill. 2021 Jan 11;7(1):e24569
pubmed: 33427687
Health Res Policy Syst. 2009 Dec 04;7:27
pubmed: 19961591
Health Econ Rev. 2020 Apr 24;10(1):11
pubmed: 32333114
J Clin Epidemiol. 2014 Dec;67(12):1291-4
pubmed: 25034198
Syst Rev. 2020 Nov 4;9(1):254
pubmed: 33148319
Res Nurs Health. 2000 Aug;23(4):334-40
pubmed: 10940958
Int J Evid Based Healthc. 2015 Sep;13(3):132-40
pubmed: 26360830
J Glob Health. 2017 Jun;7(1):010302
pubmed: 28567275
Health Promot Int. 2017 Jun 1;32(3):430-441
pubmed: 26508665
Global Health. 2021 Apr 23;17(1):50
pubmed: 33892757
Syst Rev. 2019 Apr 11;8(1):94
pubmed: 30971313
Health Policy. 2017 May;121(5):481-494
pubmed: 28359550
Niger J Clin Pract. 2015 Jul-Aug;18(4):437-44
pubmed: 25966712
Cochrane Database Syst Rev. 2021 Feb 22;2:CD011512
pubmed: 33617665
Int J Equity Health. 2014 Apr 29;13:33
pubmed: 24779653
J Health Popul Nutr. 2013 Dec;31(4 Suppl 2):106-28
pubmed: 24992806
Lancet. 2012 Sep 8;380(9845):933-43
pubmed: 22959390
Health Policy Plan. 2011 Mar;26(2):93-104
pubmed: 20813837
Sex Reprod Health Matters. 2020 Dec;28(2):1779632
pubmed: 32530387
Syst Rev. 2018 Sep 11;7(1):136
pubmed: 30205846
Health Policy Plan. 2021 May 17;36(4):572-584
pubmed: 33624113
BMJ Glob Health. 2018 Feb 06;3(1):e000505
pubmed: 29564155
Glob Health Action. 2014 Dec 03;7:25856
pubmed: 25476931
Int J Health Plann Manage. 2019 Oct;34(4):e1387-e1404
pubmed: 31311065
Bull World Health Organ. 2010 Jun;88(6):402
pubmed: 20539847
J Health Popul Nutr. 2013 Dec;31(4 Suppl 2):81-105
pubmed: 24992805
Int J Equity Health. 2018 Jan 29;17(1):13
pubmed: 29378585
BMC Health Serv Res. 2017 Apr 5;17(1):252
pubmed: 28381276
Health Res Policy Syst. 2018 Feb 05;16(1):4
pubmed: 29402314
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Glob Health Res Policy. 2021 Mar 1;6(1):8
pubmed: 33641673
Implement Sci. 2010 Sep 20;5:69
pubmed: 20854677
BMJ. 2016 Oct 21;355:i5440
pubmed: 27797786
PLoS Med. 2014 Sep 22;11(9):e1001701
pubmed: 25244520
Bull World Health Organ. 2012 Sep 1;90(9):685-92
pubmed: 22984313
Int J Equity Health. 2014 Feb 21;13:20
pubmed: 24559409
BMJ Glob Health. 2019 Aug 16;4(Suppl 8):e001481
pubmed: 31478024
Health Policy. 2018 May;122(5):493-508
pubmed: 29544900
Lancet. 2020 5-11 Sep;396(10252):693-724
pubmed: 32334655
Global Health. 2020 Jan 9;16(1):5
pubmed: 31918730
Annu Rev Public Health. 2008;29:399-409
pubmed: 18031224
Int J Equity Health. 2014 Oct 10;13:72
pubmed: 25928840
PLoS One. 2017 Feb 2;12(2):e0170996
pubmed: 28151946
PLoS Med. 2020 Nov 2;17(11):e1003368
pubmed: 33137099
J Clin Epidemiol. 2019 May;109:99-110
pubmed: 30708176
Support Care Cancer. 2020 Oct;28(10):4645-4665
pubmed: 32653957
BMJ Glob Health. 2018 Oct 10;3(Suppl 4):e000970
pubmed: 30364329
J Clin Epidemiol. 2011 Dec;64(12):1325-30
pubmed: 21937195
PLoS One. 2019 Aug 28;14(8):e0219731
pubmed: 31461458
Int J Equity Health. 2019 Dec 21;18(1):198
pubmed: 31864355
BMC Health Serv Res. 2018 Jun 7;18(1):426
pubmed: 29879978
Health Econ. 2016 Feb;25 Suppl 1:29-41
pubmed: 26775571
Rev Bras Enferm. 2021 Jun 18;74(3):e20190906
pubmed: 34161496
BMC Health Serv Res. 2015 Dec 08;15:543
pubmed: 26645355
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32847825
Int J Equity Health. 2018 Sep 27;17(1):155
pubmed: 30261882
BMC Health Serv Res. 2020 Aug 25;20(1):790
pubmed: 32843033
Syst Rev. 2016 Nov 14;5(1):190
pubmed: 27842604

Auteurs

Dominika Bhatia (D)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada dominika.bhatia@mail.utoronto.ca.

Sujata Mishra (S)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Abirami Kirubarajan (A)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Bernice Yanful (B)

Public Health Sciences Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Sara Allin (S)

Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Erica Di Ruggiero (E)

Public Health Sciences Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH